2023
Levodopa for Dystonia in Children: A Case Series and Review of the Literature
DeArias A, Bamford N. Levodopa for Dystonia in Children: A Case Series and Review of the Literature. Pediatric Neurology 2023, 152: 16-19. PMID: 38176223, DOI: 10.1016/j.pediatrneurol.2023.12.012.Peer-Reviewed Original ResearchMotor functionMarsden Dystonia Rating ScaleLimited effective treatment optionsDystonia Rating ScaleEffective treatment optionForms of dystoniaLong-term treatmentShort-term useDopa-responsive dystoniaCarbidopa-levodopaBurke-FahnRetrospective reviewCase seriesHyperkinetic movementsTreatment optionsUntoward effectsExamination notesDystoniaSignificant causeLevodopaRating ScaleTrial periodChildrenTreatmentReview
2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances 2022, 4: vdac041. PMID: 35664553, PMCID: PMC9154335, DOI: 10.1093/noajnl/vdac041.Peer-Reviewed Original ResearchProgression-free survivalRandomized phase II trialPhase II trialBevacizumab monotherapyRecurrent glioblastomaII trialTreatment armsMedian progression-free survivalLimited effective treatment optionsPhase IQuestionable survival benefitEarly clinical dataEffective treatment optionPhase IIQuality of lifeCombination armPrimary endpointAdverse eventsSurvival benefitLife scoresPoor prognosisTreatment optionsMechanisms of resistanceBevacizumabClinical data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply